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Pharmaceutical Risk and
the Quality of Life
Beat Hiltbrunner and Andreas Breitsprecher*
Introduction
"I am giving you medicine, not a poison." What appears to be an
oath from the pen of a doctor or pharmaceutical representative is in fact
from the drama "Nathan der Weise" by the German poet Lessing and
was written in 1779. However, this quotation is still relevant today.
Apart from their benefits, drugs always entail a risk. Thus, closely
associated with the quotation from Lessing are questions with regard to
drug safety and the ratio of accompanying risks and a possible increase
in the chances of cure or improvement in the quality of life.
Individual acceptance of risks generally, or those posed by
pharmaceuticals specifically, is a function of more than their frequency
and severity. It is also a function of what benefit one expects to gain
from assuming a risk, and both the evaluation of risk and the evaluation
of benefit tend to be quite subjective.
Recently, investigators have attempted to get a better grasp of risk
and benefit perceptions through "quality-of-life" studies which ask
patients to complete questionnaires. 1 The main objective of this paper
is to briefly review what it is that these instruments attempt to measure
* Dr. Hiltbrunner is head of the quality of life research group at Ciba-Geigy Ltd.,
Basel, Switzerland. He received his medical training at the University of Lusanne and
has completed residencies in pediatrics and neurology in the United States. Mr.
Breitsprecher is the Head of Public Communication Pharma, Ciba-Geigy, Ltd.
1 See generally, e.g., QUALITY OF LIFE ASSESSMENTS IN CLINICAL TRIALS
(B. Spilker ed. 1990). See also, Merz, An Empirical Analysis of the Medical
Informed Consent Doctrine: Search for a Standard of Disclosure, infra 27, at 54.
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and the potential for use of such research in the evaluation of drugs.
Risk Acceptance Generally
During our life, we are confronted with an indeterminable number of
risks. We have to estimate them and then decide whether we are
prepared to take these risks in the light of the expected benefits. It is
well known that there is no such thing as zero risk. Nevertheless,
there's a growing tendency in society to avoid taking risks. A sort of
"zero-risk society" is emerging - a society that is attempting to protect
itself as far as possible from everything forever. This is in fact a
paradox. It is precisely in the western industrialized countries with
growing technical advance and affluence that we are living in an
environment where risks are increasing at a similar rate. One would be
justified in claiming that industry tends to increase the number of risks,
not only for some individuals but for society as a whole. One can think
of the dangers involved in industrial production and use and in the
problems of subsequent disposal of wastes. No one would wish to
dispute the fact that the use of the car - a symbol of technical progress
- involves enormous risks. The same applies to the possible
consequences of everyday stress, incorrect nutrition or the consumption
of nicotine and alcohol and environmental pollution. Viewed
objectively, the risk-shy industrial citizen is thus exposing himself to
very serious risks.
We have to accept some risks. However, we are confronted with the
problem of trying to fit risk acceptance into a scientific framework.
What is acceptable in the individual case, and what is not? And by
which criteria and with which means can the individual determine this?
In this context, what certainly plays a role is the fact that people
associate certain things with the subjective idea of high or low potential
risks - regardless of the actual existing dangers. Thus, in statistical
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terms, the probability of dying in a car accident is significantly higher
than death from the effects of a drug.2 Nevertheless, drugs as a whole
are classed as being more dangerous. The benefit/risk evaluation applied
to drugs gives a completely different result compared with the evaluation
in the case of a car.
Apart from a lack of information, the reason is certain also to be
found in the tendency toward different evaluation of perceptions, which
often confuses the desirable with the actual. The daily report on
automobile accidents is certainly not as spectacular as an air crash or a
dramatic drug offense report. Nevertheless, in the decision-making
process, everyone daily makes his own, generally subjective, risk
evaluation on the basis of information available to him. This also applies
to the sensitive area of drugs.
Drug Risks
The pharmaceutical industry contributes to the existence of risk in
two ways. First, research and technical and administrative activities give
rise to possible risks which affect safety of the workplace, the
inhabitants of the surroundings or of the whole environment. These are
factors which are becoming more and more important in society. This
branch of industry invests considerable sums of money and human
resources in the investigation of industrial risks and in the development
of suitable technologies to reduce risks posed by its activities. Second,
the products of the pharmaceutical industry are possible sources of risk.
As noted earlier, drug safety has long been a matter of concern.
Medicaments must meet in particular the three main criteria of "quality",
"efficacy" and "safety" - safety clearly being the most sensitive area.
The ethical responsibility of science, medicine and the
pharmaceutical industry to minimize drug safety is undisputed. A true
2 Heilmann, Das Arzneimittel als Risiko, PHARMA DIALOG 82 (1984).
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awareness of the existence of drug-related risks among the broad
population first emerged in the 1960's as a result of the thalidomide
tragedy. This case initiated a radical change in the public's perception of
risks associated with the effects of drugs.
In the past, evaluation of the risk of drugs was based on
spontaneous reports of side effects, post-marketing surveillance studies
or literature evaluations. Nowadays, much more precise studies of drug
risks are required. They include extensive compilation of side effects in
the international context, safety evaluations in clinical studies, and
biochemical and genetic studies. Pharmacoepidemiology, a relatively
recent branch of science, tries to achieve progress along the path to
greater drug safety by international networking and worldwide data
exchange.
Yet, it would be utopian to believe in the possibility of developing,
in the foreseeable future, medicaments without more or less severe
adverse effects. One has to live with the risk associated with drugs, but
the risk has to be viewed as a function of the therapy. Serious risks tend
to be rare and minimal risks comparatively frequent. The central aspect
in the determination and evaluation of drug risks is to achieve the
maximum possible benefit in conjunction with the minimum possible
risk of adverse effects to the patient.
Which risk of adverse effects is acceptable or unacceptable in the
individual case? What standards must be set? In the case of life-
threatening diseases, such as AIDS or cancer, answers are fairly easy to
obtain. However, in the large number of chronically stationary diseases,
the degree of a successful treatment tends to vary over ranges which are
difficult to measure.
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Risk and Quality of Life
There is no doubt that the introduction of effective antibiotics against
tuberculosis since the middle of our century has resulted in an
improvement in the quality of life of tuberculosis patients. However, an
attempt rigorously to measure quality of life has only recently taken
place.3 The importance of such evaluations in connection with drug
treatment is increasing insofar as people are living longer, and the
quality of life is of increasing priority to older people.4
Improved quality of life has traditionally been regarded as an
inevitable consequence of declining disease or life-prolonging measures.
However, it has been shown that the quality of life, as patients assesses
it, may deteriorate despite an "objectively" successful treatment.
If the risk of dangerous side effects is high compared with the
benefits, the drug usually has to be withdrawn from the market. If the
risk is comparatively small and the benefits are large, a risk/benefit
assessment is also straight-forward. However, the risk/benefit ratio of
most marketable medications fall between these two extremes. In such
circumstances, the results of quality-of-life studies can aid doctors and
patients in choosing to pursue a method of treatment.
Also, quality-of-life information may be unnecessary if, using
conventional disease parameters, the therapeutic efficacy of a new drug
is clearly superior to existing treatments. Yet, such information may be
very valuable where conventional clinical parameters cannot distinguish
alternative therapies. Quality-of-life measurements of apparently equally
effective methods of treatment may, if the profiles of the side effects or
the action mechanism of a new medicament differ, help patients to
decide between possible treatments.
3 Luce, QoL and the Pharmaceutical Industry: A Perspective, QUALITY OF LIFE
AND CARDIOVASCULAR CARE 191-192 (1988).
4 Wertheimer and Nickman, Drug Therapy and Quality of Life, QUALITY OF LIFE
AND CARDIOVASCULAR CARE 13-22 (1985).
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Possibilities and Limits in Practical Use
The term "quality of life" usually covers five dimensions which
constitute the main areas of human well-being: physical, social,
intellectual, emotional and economic. There are two general types of
quality-of-life studies. Some investigate general health studies, and
others examine specific diseases. Both employ questionnaires which
have to be completed by the patient, but such studies pose a number of
questions. Particularly difficult is a suitable method of measurement for
comparative evaluations of the quality of life.
The use of general health questionnaires is particularly suitable to
compare the quality of life of patients with different diseases or
treatment. However, they do not tend to be sufficiently sensitive to
differentiate between the effects of similar treatments.
Disease-specific quality-of-life investigations are used to study
particular aspects of a disease, for example, the effects of different
treatments on the quality of life, their different benefits and their
different risks. They cannot be used for other diseases. If the influence
of two different hormone treatments on the quality of life of women in
the menopause are studied, questions regarding the use of a wheelchair,
the need for assistance to move from the bed or the inability of the
person to dress herself may be of no importance. In contrast, hot
flushes and dryness of the vagina have major impact on the quality of
life of these patients but not of patients with chronic polyarthritis or
hereditary diabetes melitus.
Quality-of-life instruments which are developed for a particular
patient population are often not transferable to patients across cultures.
Adapting instruments to new cultural or linguistic conditions is usually a
time-consuming and expensive process.
Additional matters further complicate quality-of-life studies. They
can be influenced by a wide range of health and demographic
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characteristics. In order to separate treatment effects on patient quality of
life from other considerations - for example, concurrent diseases - it
may be necessary to select subpopulations of patients. This may lead to
loss of general validity of the results, a matter with potentially important
regulatory consequences.
Studies to determine treatment related improvement in the quality of
life may be particularly important in the case of chronic diseases such as
rheumatoid arthritis, in advanced stages of cancer, or asymptomatic
diseases such as essential hypertension. In the case of progressive
diseases, such as cancer, an improvement of the patient's quality of life
as a result of therapy may be interesting but not satisfactory unless the
duration of the improvement is measured. Unfortunately, few validated
quality-of-life instruments can be used repeatedly every two to four
weeks.
Studies on the effects of treatments on the quality of life of children,
elderly people and the mentally retarded entail special difficulties, and
the first steps to resolve them have only just been taken. Additional
problems arise from the effects which the treatment of these patients
have on their social environment - especially on parents or spouse.
If a treatment leads to an improvement in the parameters of the
disease, as well as in the quality of life, the therapeutic intervention is
useful. If improvement is shown to the advantage of one drug over
another, depending on economic circumstances, health authorities may
be more willing to permit or even to favor its use.
Conclusion
Quality-of-life research is generally classified under the "soft
sciences" and may not offer the precision that some people would
desire. Yet, studies in certain cases, make it possible to record
quantitatively the personal risk assessment of a patient and to take the
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results into account for a risk/benefit analysis. Such studies can be used
to complete a registration dossier as a parameter of efficacy. Because of
their potential, they can also be used to study the influence of a treatment
on the social environment. Therefore, they may figure into price
negotiations. However, quality-of-life evaluations are in their infancy
and still entail uncertainties and problems.
Until recently, quality-of-life research has been primarily done at
universities. However, over the past ten years, the pharmaceutical
industry has begun to play a role.5 In the future and particularly as
some of the scientific difficulties are overcome, it is expected that the
pharmaceutical industry will become even more active in planning,
implementation and evaluation of quality-of-life studies.
5 Bombardier, Ware, Russell, et al., Auranofin Therapy and Quality of Life in
Patients with Rheumatoid Arthritis, 81 AM. J. MED. 565-578 (1986). Croog,
Levin, Testa, et al., The Effects of Antihypertensive Therapy on the Quality of Life,
314 N. ENG. J. MED. 1657-1664 (1986).
